
Using commercial AI-based mammography analysis software to improve breast US interpretations
This study evaluated the use of commercial AI-based mammography software to improve breast ultrasound (US) lesion interpretations. The AI software, which provides an AI malignancy score ranging from 0 to 100, was tested on 1,109 breasts that underwent both mammography and US-guided breast biopsy. The AI software showed an area under the curve (AUROC) of 0.79 for distinguishing benign from